Testing BV-AVD Treatment for Adults with Newly Diagnosed Early Stage Bulky Hodgkin Lymphoma Using PET and Tumor Volume Guidance

What this Trial Is About

Researchers are evaluating the combination of brentuximab vedotin BV with AVD chemotherapy in people recently diagnosed with early stage, bulky Hodgkin lymphoma who have not yet received treatment. This Phase 2 study aims to see if adding BV, a targeted drug that attacks cancer cells expressing CD30, to standard chemotherapy can better slow or stop lymphoma growth compared to chemotherapy alone. The study is sponsored by Memorial Sloan Kettering Cancer Center. Participants will receive two cycles of BV combined with AVD chemotherapy, supported by growth factor injections to help blood cell recovery. After these two cycles, patients undergo an FDG-PETCT scan to assess response. Those with no progression receive two more cycles of BV-AVD without additional therapy. Patients with partial or stable disease are further assessed by tumor volume and may receive extra cycles of BV-AVD plus radiation if they have low tumor volume. Treatment doses and schedules involve intravenous administration on specific days within 28-day cycles. Throughout the study, participants have scans and clinical evaluations to monitor disease status and side effects. Researchers measure progression-free survival over three years as the primary outcome, with overall survival also tracked. Safety and response are closely observed, with patients leaving the study if disease progresses. The total participation period extends to several years for follow-up evaluations.

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma